EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for breast cancer-related peritoneal carcinomatosis: rationale, evidence, and future directions

Noor Al Eman, Nida Nasimzada, Adam Taleb, Mohab Shanash, Khalid Osama Alnajjar, Mohammed Alfuwais, Amal Alhefdhi, Ayman Azzam, Ihssan Alalem

Frontiers in Oncology · 09.11.2026 · 16

DOI: 10.3389/fonc.2026.2016662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Noor Al Eman und 8 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal carcinomatosis (PC) from breast cancer is a rare but clinically significant manifestation of stage IV disease, most commonly associated with invasive lobular carcinoma and specific molecular subtypes. Systemic chemotherapy has limited efficacy in this setting due to poor peritoneal drug penetration and the physiological peritoneal-plasma barrier. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a promising locoregional strategy, delivering heated chemotherapy directly into the peritoneal cavity following maximal cytoreduction. While evidence from retrospective series suggests meaningful survival benefit in selected patients — with overall survival reaching 49 months in some cohorts — no prospective randomized data specific to breast cancer currently exist. This review evaluates the biological rationale, available clinical evidence, prognostic factors including the peritoneal cancer index and completeness of cytoreduction score, procedural risks, and future directions for CRS-HIPEC in breast cancer-related PC. The potential role of emerging systemic agents, precision medicine tools, and minimally invasive intraperitoneal strategies is also discussed.

Zitieren

APA

Eman, N. A., Nasimzada, N., Taleb, A., Shanash, M., Alnajjar, K. O., Alfuwais, M., Alhefdhi, A., Azzam, A., & Alalem, I. (2026). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for breast cancer-related peritoneal carcinomatosis: rationale, evidence, and future directions. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2016662

Vancouver

Eman NA, Nasimzada N, Taleb A, Shanash M, Alnajjar KO, Alfuwais M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for breast cancer-related peritoneal carcinomatosis: rationale, evidence, and future directions. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2016662

BibTeX
@article{Eman2026,
  author = {Eman, Noor Al and Nasimzada, Nida and Taleb, Adam and Shanash, Mohab and Alnajjar, Khalid Osama and Alfuwais, Mohammed and Alhefdhi, Amal and Azzam, Ayman and Alalem, Ihssan},
  title = {Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for breast cancer-related peritoneal carcinomatosis: rationale, evidence, and future directions},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.2016662}
}
Kostenlos starten →